Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM-5
2023-509208-14-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Elranatamab monotherapy, Elranatamab + daratumumab and Daratumumab + pomalidomide + dexamethasone (3 arms). Primary endpoints: Dose-limiting toxicities, Progression-free survival and 1 more. Planned start Sep 2021; status: authorised.
02
Drugs
elranatamabdaratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-509208-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509208-14-00.